A detailed history of Virtus ETF Advisers LLC transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 7,423 shares of RYTM stock, worth $414,574. This represents 0.19% of its overall portfolio holdings.

Number of Shares
7,423
Previous 7,423 -0.0%
Holding current value
$414,574
Previous $304,000 27.63%
% of portfolio
0.19%
Previous 0.15%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$35.41 - $44.37 $51,379 - $64,380
-1,451 Reduced 16.35%
7,423 $304,000
Q1 2024

May 15, 2024

BUY
$39.12 - $52.44 $49,956 - $66,965
1,277 Added 16.81%
8,874 $384,000
Q4 2023

Feb 15, 2024

SELL
$21.39 - $49.64 $205,258 - $476,345
-9,596 Reduced 55.81%
7,597 $349,000
Q3 2023

Nov 07, 2023

SELL
$15.81 - $27.8 $35,114 - $61,743
-2,221 Reduced 11.44%
17,193 $394,000
Q2 2023

Aug 14, 2023

BUY
$16.32 - $21.15 $147,043 - $190,561
9,010 Added 86.6%
19,414 $320,000
Q1 2023

May 15, 2023

BUY
$16.88 - $34.24 $3,089 - $6,265
183 Added 1.79%
10,404 $185,000
Q4 2022

Feb 14, 2023

BUY
$22.21 - $30.25 $227,008 - $309,185
10,221 New
10,221 $297,000
Q2 2022

Aug 12, 2022

SELL
$3.12 - $12.25 $50,909 - $199,883
-16,317 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$6.13 - $12.24 $5,964 - $11,909
-973 Reduced 5.63%
16,317 $188,000
Q4 2021

Feb 14, 2022

BUY
$8.62 - $13.9 $60,865 - $98,147
7,061 Added 69.03%
17,290 $173,000
Q3 2021

Nov 15, 2021

SELL
$11.68 - $20.72 $6,260 - $11,105
-536 Reduced 4.98%
10,229 $134,000
Q2 2021

Aug 10, 2021

BUY
$18.52 - $22.55 $15,297 - $18,626
826 Added 8.31%
10,765 $211,000
Q1 2021

May 17, 2021

BUY
$20.25 - $39.49 $3,381 - $6,594
167 Added 1.71%
9,939 $211,000
Q4 2020

Feb 12, 2021

SELL
$21.17 - $32.61 $118,806 - $183,007
-5,612 Reduced 36.48%
9,772 $291,000
Q3 2020

Nov 13, 2020

SELL
$18.13 - $30.61 $38,073 - $64,281
-2,100 Reduced 12.01%
15,384 $333,000
Q2 2020

Aug 05, 2020

BUY
$14.41 - $25.35 $32,566 - $57,291
2,260 Added 14.84%
17,484 $390,000
Q1 2020

May 14, 2020

SELL
$13.16 - $22.9 $29,294 - $50,975
-2,226 Reduced 12.76%
15,224 $232,000
Q4 2019

Feb 13, 2020

BUY
$19.53 - $25.5 $119,953 - $156,621
6,142 Added 54.32%
17,450 $401,000
Q3 2019

Nov 12, 2019

SELL
$18.62 - $24.51 $11,730 - $15,441
-630 Reduced 5.28%
11,308 $244,000
Q2 2019

Aug 13, 2019

BUY
$21.11 - $28.48 $52,141 - $70,345
2,470 Added 26.09%
11,938 $263,000
Q1 2019

May 14, 2019

SELL
$24.76 - $31.66 $25,849 - $33,053
-1,044 Reduced 9.93%
9,468 $260,000
Q4 2018

Feb 05, 2019

SELL
$24.11 - $31.34 $85,156 - $110,692
-3,532 Reduced 25.15%
10,512 $283,000
Q3 2018

Nov 14, 2018

SELL
$26.99 - $35.85 $278,806 - $370,330
-10,330 Reduced 42.38%
14,044 $410,000
Q2 2018

Aug 10, 2018

BUY
$17.02 - $35.2 $414,845 - $857,964
24,374 New
24,374 $762,000

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $3.11B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.